AVBP

ArriVent BioPharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website arrivent.com
Employees(FY) 42
ISIN US04272N1028

Performance

+0.81%

-4.85%

+7.81%

+49.0%

+30.45%

YTD

+30.45%

Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of AVBP 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23 indicating strong bearish momentum, the Oscillators Score at 46 suggesting a neutral stance, and the Technical Score at 35 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend leans towards w...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AVBP

Stock Rank

Recent News & Updates

2024-11-14 08:29
ArriVent BioPharma's Q3 Net Loss Narrows(MT Newswires)
2024-11-14 08:00
ArriVent BioPharma Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-13 19:00
ArriVent BioPharma Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-10-11 19:02
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc(GuruFocus.com)
2024-09-10 08:17
Oppenheimer Adjusts Price Target on ArriVent BioPharma to $39 From $35, Maintains Outperform Rating(MT Newswires)
2024-09-09 13:06
ArriVent BioPharma Lung Cancer Treatment Study Shows Positive Interim Results(MT Newswires)
2024-09-09 12:05
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer(GlobeNewswire)
2024-09-09 00:05
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer(Globenewswire)
2024-09-06 07:49
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate(Simply Wall St.)
2024-08-19 09:55
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet(Zacks)
2024-08-14 17:26
ArriVent BioPharma Q2 Net Loss Narrows(MT Newswires)
2024-08-14 16:01
ArriVent BioPharma Reports Second Quarter 2024 Financial Results(GlobeNewswire)
2024-08-14 09:54
AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024(Investorplace)
2024-08-14 04:01
ArriVent BioPharma Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-12 08:00
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer(GlobeNewswire)
2024-08-11 20:00
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer(Globenewswire)
2024-07-27 09:02
ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%(Simply Wall St.)
2024-07-22 08:10
Oppenheimer Initiates Coverage on ArriVent BioPharma With Outperform Rating, $35 Price Target(MT Newswires)
2024-06-05 07:00
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab(GlobeNewswire)
2024-06-04 19:00
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab(Globenewswire)
2024-05-16 16:05
ArriVent Appoints John Hohneker, M.D., to its Board of Directors(GlobeNewswire)
2024-05-16 04:05
ArriVent Appoints John Hohneker, M.D., to its Board of Directors(Globenewswire)
2024-05-08 08:00
ArriVent BioPharma Reports First Quarter 2024 Financial Results(GlobeNewswire)
2024-05-08 00:54
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024(Investorplace)
2024-05-07 20:00
ArriVent BioPharma Reports First Quarter 2024 Financial Results(Globenewswire)
2024-04-22 16:05
ArriVent Appoints Kristine Peterson to its Board of Directors(GlobeNewswire)
2024-04-22 04:05
ArriVent Appoints Kristine Peterson to its Board of Directors(Globenewswire)
2024-03-28 16:05
ArriVent BioPharma Reports Full Year 2023 Financial Results(GlobeNewswire)
2024-03-28 04:05
ArriVent BioPharma Reports Full Year 2023 Financial Results(Globenewswire)
2024-02-04 23:59
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More(Insidermonkey)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.